Spin-lattice instability to a fractional magnetization state in the spinel HgCr2O4

Magnetic systems are fertile ground for the emergence of exotic states when the magnetic interactions cannot be satisfied simultaneously due to the topology of the lattice - a situation known as geometrical frustration. Spinels, AB2O4, can realize the most highly frustrated network of corner-sharing tetrahedra. Several novel states have been discovered in spinels, such as composite spin clusters and novel charge-ordered states. Here we use neutron and synchrotron X-ray scattering to characterize the fractional magnetization state of HgCr2O4 under an external magnetic field, H. When the field is applied in its Neel ground state, a phase transition occurs at H ~ 10 Tesla at which each tetrahedron changes from a canted Neel state to a fractional spin state with the total spin, Stet, of S/2 and the lattice undergoes orthorhombic to cubic symmetry change. Our results provide the microscopic one-to-one correspondence between the spin state and the lattice distortion

Multidisciplinary approach to diagnosis and management of osteosarcoma – a review of the St Vincent's Hospital experience

BACKGROUND: Osteosarcoma is the most common primary malignant bone tumour in children and young adults. Despite advances in the diagnosis and management of osteosarcoma, there have been few recent studies describing the experiences of tertiary referral centres. This paper aims to describe and discuss the clinical features, pre-operative work-up, management and outcomes of these patients at St Vincent's Hospital (Melbourne, Australia). METHODS: Retrospective study of fifty-nine consecutive patients managed for osteosarcoma at St Vincent's Hospital between 1995 and 2005. RESULTS: Median age at diagnosis was 21 (range, 11–84) years. Gender distribution was similar, with thirty-one male and twenty-eight female patients. Twenty-five patients had osteosarcoma in the femur, eleven each were located in the humerus and tibia, six were identified in the pelvis, and one each in the clavicle, maxilla, fibula, sacrum, ulna and radius. Pre-operative tissue diagnosis of osteosarcoma was obtained through computed tomography-guided percutaneous biopsy in over ninety percent of patients. Following initial therapy, over fifty percent of patients remained relapse-free during the follow-up period, with twelve percent and twenty-seven percent of patients documented as having local and distant disease recurrence, respectively. Of patients with recurrent disease, sixty-two percent remained disease-free following subsequent surgical intervention (most commonly, pulmonary metastatectomy). CONCLUSION: Patient outcomes can be optimised through a multidisciplinary approach in a tertiary referral centre. At St Vincent's Hospital, survival and relapse rates of patients managed for osteosarcoma compare favourably with the published literature

A superconvergent hybridisable discontinuous Galerkin method for linear elasticity

The first super‐convergent hybridisable discontinuous Galerkin (HDG) method for linear elastic problems capable of using the same degree of approximation for both the primal and mixed variables is presented. The key feature of the method is the strong imposition of the symmetry of the stress tensor by means of the well‐known and extensively used Voigt notation, circumventing the use of complex mathematical concepts to enforce the symmetry of the stress tensor either weakly or strongly. A novel procedure to construct element‐by‐element a super‐convergent post‐processed displacement is proposed. Contrary to other HDG formulations, the methodology proposed here is able to produce a super‐convergent displacement field for low order approximations. The resulting method is robust and locking‐free in the nearly incompressible limit. An extensive set of numerical examples is utilised to provide evidence of the optimality of the method and its super‐convergent properties in two and three dimensions and for different element types

Are we killing them with kindness? Evaluation of sustainable marine wildlife tourism

The increasing popularity of marine wildlife tourism (MWT) worldwide calls for assessment of its conservation outcomes and the development of appropriate management frameworks to ensure the conservation of the species and habitats involved as well as the long-term sustainability of this industry. While many studies have examined the positive and/or negative implications of particular forms of MWT, few have attempted to identify factors of concern shared across different types of marine tourism, or examine their implications for sustainability in a broader perspective. We reviewed the existing literature to highlight common impacts on animal behaviour, health and ecology, and to identify successful cases based on minimal negative affects and/or lack of chronic/ irreversible impacts on target species or habitats. To ensure the achievement of both economic and ecologic objectives, the following steps should be integrated in MWT management: 1) Increase of research on the biology and ecology of target species/habitat and application of relevant information for the development of suitable policies, frameworks and management strategies; 2) Structured enforcement of existing policies and enhancement of ecological awareness of visitors through active education; 3) Application of an adaptive management framework to continuously improve the codes of conduct employed; 4) Involvement of different stakeholders and local communities in the development and improvement of the MWT activity. Combining these strategies with the extrapolation of frameworks and policies from cases where adverse ecological impacts have been addressed and successfully resolved can further contribute in ensuring the long-term health and conservation of the species/ habitats involved in MWT activities

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

To determine intrinsic breast cancer subtypes represented within categories defined by quantitative hormone receptor (HR) and HER2 expression

The status of platinum anticancer drugs in the clinic and in clinical trials

Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered clinical trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations. During this time there have been more failures than successes with the development of 14 drugs being halted during clinical trials. Currently there are four drugs in the various phases of clinical trial (satraplatin, picoplatin, LipoplatinTM and ProLindacTM). No new small molecule platinum drug has entered clinical trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade. In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials, and discuss the results in the context of where we believe the field will develop over the next decade

Progress and prospects for event tourism research

This paper examines event tourism as a field of study and area of professional practice updating the previous review article published in 2008. In this substantially extended review, a deeper analysis of the field’s evolution and development is presented, charting the growth of the literature, focusing both chronologically and thematically. A framework for understanding and creating knowledge about events and tourism is presented, forming the basis which signposts established research themes and concepts and outlines future directions for research. In addition, the review article focuses on constraining and propelling forces, ontological advances, contributions from key journals, and emerging themes and issues. It also presents a roadmap for research activity in event tourism

Genome-Wide Analyses Reveal a Role for Peptide Hormones in Planarian Germline Development

Genomic/peptidomic analyses of the planarian Schmidtea mediterranea identifies >200 neuropeptides and uncovers a conserved neuropeptide required for proper maturation and maintenance of the reproductive system

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Background Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy. Methods To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standard-schedule first-event rate ratios (RRs). Findings Individual patient data were provided for 26 of 33 relevant trials identified, comprising 37 298 (93%) of 40 070 women randomised. Most women were aged younger than 70 years and had node-positive disease. Total cytotoxic drug usage was broadly comparable in the two treatment arms; colony-stimulating factor was generally used in the more dose-intense arm. Combining data from all 26 trials, fewer breast cancer recurrences were seen with dose-intense than with standard-schedule chemotherapy (10-year recurrence risk 28·0% vs 31·4%; RR 0·86, 95% CI 0·82–0·89; p<0·0001). 10-year breast cancer mortality was similarly reduced (18·9% vs 21·3%; RR 0·87, 95% CI 0·83–0·92; p<0·0001), as was all-cause mortality (22·1% vs 24·8%; RR 0·87, 95% CI 0·83–0·91; p<0·0001). Death without recurrence was, if anything, lower with dose-intense than with standard-schedule chemotherapy (10-year risk 4·1% vs 4·6%; RR 0·88, 95% CI 0·78–0·99; p=0·034). Recurrence reductions were similar in the seven trials (n=10 004) that compared 2-weekly chemotherapy with the same chemotherapy given 3-weekly (10-year risk 24·0% vs 28·3%; RR 0·83, 95% CI 0·76–0·91; p<0·0001), in the six trials (n=11 028) of sequential versus concurrent anthracycline plus taxane chemotherapy (28·1% vs 31·3%; RR 0·87, 95% CI 0·80–0·94; p=0·0006), and in the six trials (n=6532) testing both shorter intervals and sequential administration (30·4% vs 35·0%; RR 0·82, 95% CI 0·74–0·90; p<0·0001). The proportional reductions in recurrence with dose-intense chemotherapy were similar and highly significant (p<0·0001) in oestrogen receptor (ER)-positive and ER-negative disease and did not differ significantly by other patient or tumour characteristics. Interpretation Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles, or by giving individual drugs sequentially rather than giving the same drugs concurrently, moderately reduces the 10-year risk of recurrence and death from breast cancer without increasing mortality from other causes. Funding Cancer Research UK, Medical Research Council

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment